Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF
Marketing
Novartis targets longer Beovu dosing interval in DME
Beovu, given at an interval of up to 16 weeks in DME, showed similar retinal vasculitis and retinal vascular occlusion rates to Regeneron's Eylea.
Angus Liu
Aug 17, 2021 10:15am
Novartis caps 3 Beovu trials on safety concerns
Jun 1, 2021 11:41am
Novartis hits setback in bid to block Eylea prefilled syringe
May 4, 2021 9:55am
Regeneron shoots for longer Eylea dosing interval with NIH data
Apr 2, 2021 8:04am
Novartis' Beovu matches Eylea in head-to-head macular edema tilt
Sep 14, 2020 11:50am
Roche, wielding new implant data, looks beyond Lucentis for wet
Aug 3, 2020 7:00am